Recent Updates
Recently added Catalysts
PODD Neutral Sentiment Score: 50/100

Insulet to Participate in William Blair 46th Annual Growth Stock Conference

Key Takeaway: Insulet Corporation is set to participate in the William Blair 46th Annual Growth Stock Conference. The event will provide an opportunity for the company to engage with investors and discuss its growth strategies. Further details about the conference and Insulet's presentation have not been disclosed.
Price reaction · baseline $153.8 (2026-05-26 close) · hit after-hours · clean, no other PODD news in the window
day 0 close
-5.1%
day 1 · peak
-7.2%
day 3
-3.7%

Market Sentiment Analysis

Full Press Release Details

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader intubeless insulin pump technologywith its Omnipod® brand of products, today announced that management will present at the William Blair 46thAnnual Growth Stock Conference in Chicago on Wednesday, June 3, 2026 at 2:00 p.m. (Central Time).
The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website:investors.insulet.com/events.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visitinsulet.comoromnipod.com.
©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved.
Last updated: May 27, 2026